3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1/2
4
Phase 1
3
Phase 3
2
Status
Recruiting
2
Not yet recruiting
2
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
2
Interventions
Carboplatin
106
Cisplatin
97
Paclitaxel
78
pembrolizumab
69
Gemcitabine
59
Pemetrexed
49
Cyclophosphamide
46
Docetaxel
45
Dexamethasone
45
durvalumab
44
Capecitabine
44
Radiotherapy
40
Nivolumab
37
Lenalidomide
37
Specimen Handling
36
Doxorubicin
36
Rituximab
34
Oxaliplatin
34
Bevacizumab
33
Magnetic Resonance Spectroscopy
32
Fluorouracil
32
atezolizumab
29
Etoposide
29
Vincristine
26
Radiation
26
Leucovorin
26
Letrozole
24
Bortezomib
24
Fulvestrant
23
Prednisone
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Active not recruiting
×
Pluvicto
×
Clear all
NCT04720157
2026-05-27
PSMAddition
Novartis
Phase 3
Active not recruiting
1,140 enrolled
NCT04689828
2026-03-23
PSMAfore
Novartis
Phase 3
Active not recruiting
469 enrolled
11 charts
1 FDA